Zedira receives a research grant of 750,000 Euros for the development of novel compounds for thromboprophylaxis
As part of the funding program "KMU-innovativ", Zedira will receive a research grant of 750,000 Euros over a period of two years from the Federal Ministry of education and Research. Zedira plans to expand its drug development pipeline based on proprietary inhibitors that specifically target blood coagulation factor XIII. This important protein in the blood coagulation cascade belongs to a family of enzymes known as transglutaminases.
The biopharmaceutical company leads a consortium integrating academic groups in structural biology in Marburg with pharmacological hemostaseology in Jena.
Dr. Martin Hils, Chief Executive Officer of Zedira, comments: “We are proud that our development project was chosen for this renowned and competitive funding program”.
Dr. Ralf Pasternack, Chief Executive Officer of Zedira, adds: “While Zedira has successfully developed tissue transglutaminase inhibitors addressing celiac disease, the grant enables us to broaden our scope. Based on proprietary small-molecule inhibitors, Zedira is on its way to strengthening its leading position in diseases linked to transglutaminases”.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
